Recursion Pharmaceuticals
Recursion is a publicly traded TechBio company that uses large-scale automated cell imaging and AI to discover and develop drugs, running its own clinical pipeline in oncology, rare disease, and neuroscience.
Evidence notes
Who uses it: Recursion operates as an integrated drug discoverer (internal pipeline owner) and platform licensor/partner to large pharma R&D organizations that want to access its data, models, or discovery capabilities without building the infrastructure themselves.[8]+5Company-authored
Public signals: Recursion OS 2.0 platform page live, positioning end-to-end biology-to-ClinTech drug discovery engine[8]Company-authored
: Automated high-content cell imaging at scale generates a proprietary biological dataset; foundation models (including LOWE, its large biology model) are trained on that data to predict compound-disease relationships; hits are progressed through internal...
Source ledger
- [1]Recursion Pharmaceuticals Stock Price, Funding, Valuation, Revenue & Financial Statements – CB Insights
- [2]Recursion Pharmaceuticals – 2026 Funding Rounds & List of Investors – Tracxn
- [3]Recursion Pharma — Unicorn company profile | Dealroom
- [4]Top Recursion Pharmaceuticals Alternatives, Competitors
- [5]Recursion Reports First Quarter Financial Results and Provides Business Update - BioSpace